Drugs / T-DXd
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06244485 | Feb 2024 → Nov 2028 expected | neoplasm | Daiichi Sankyo | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2023-11-04 | Daiichi Sankyo | Regulatory Anvisa aprova duas novas indicações de trastuzumabe deruxtecana para tumores de pulmão e gástrico daiichisankyo.com.br ↗ |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2023-11-04 | Daiichi Sankyo | Anvisa aprova duas novas indicações de trastuzumabe deruxtecana para tumores de pulmão e gástrico daiichisankyo.com.br ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | T-DXd | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06244485 ↗ |
| Route | Intravenous | “One IV infusion Q3W on Day 1 of each 21-day cycle” NCT06244485 ↗ |